Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients
- Daxor Corporation presents new data validating the benefits of blood volume analysis (BVA).
- The study highlights the limitations of surrogate markers in measuring blood volume.
- Daxor's BVA system is shown to be 98% accurate in measuring blood volume.
- The study emphasizes the importance of accurate blood volume measurement in optimizing therapy for heart failure patients with impaired renal function.
- Daxor's technology provides clinicians with actionable data to improve outcomes and reduce the cost of care.
- None.
The recent study from Duke University Medical Center highlights the significance of accurate blood volume analysis (BVA) for heart failure patients, particularly those with impaired renal function. The findings underscore the limitations of surrogate markers like right atrial pressure and capillary wedge pressure, which have been traditionally used to guide volume decisions in clinical settings. The study's emphasis on the heterogeneity of volume status across different levels of renal function and the weak correlation between pressure and volume point to the necessity for more precise diagnostic tools in managing heart failure.
From a medical research perspective, the introduction of a 98% accurate BVA system by Daxor could represent a paradigm shift in the standard of care for heart failure patients. The ability to detect dilutional anemia, a condition more prevalent in patients with worse renal function, further solidifies the clinical utility of BVA. The implications of these findings could lead to improved patient outcomes through more tailored treatment plans, potentially reducing the duration and cost of care for a significant patient population.
From an economic standpoint, the validation of Daxor's BVA technology has the potential to influence healthcare spending on heart failure management. Heart failure is associated with high hospitalization rates and healthcare costs, particularly due to complications like renal impairment. By providing a more accurate assessment of a patient's volume status, BVA could enable clinicians to optimize treatment regimens, possibly reducing the frequency of hospital readmissions and the need for more invasive procedures.
Furthermore, the improvement in individualized care could lead to better resource allocation within healthcare systems. The long-term economic benefits could be substantial, considering the prevalence of heart failure and the associated costs. The adoption of BVA technology could also drive market demand for Daxor's products, potentially impacting the company's financial performance and investor interest.
From a market perspective, Daxor's BVA diagnostic tool is positioned in a niche yet critical segment of the healthcare market—heart failure diagnostics. With the validation from a reputable institution like Duke University Medical Center, Daxor is likely to experience increased credibility and visibility within the medical community. This could translate into greater adoption rates of their BVA system and expansion into new clinical areas.
The study's results could also prompt a reevaluation of current diagnostic standards, possibly leading to updated clinical guidelines that favor BVA technology. Such changes could have a ripple effect on the diagnostic market, influencing competitor strategies and accelerating innovation. Stakeholders, including investors, should monitor the adoption curve and any shifts in regulatory recommendations that could further solidify Daxor's market position.
Only Daxor’s BVA Diagnostic Was Shown to Accurately Reflect Blood Volume Compared to Inferior Surrogates
Oak Ridge, TN, March 08, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data from Duke University Medical Center validating the benefits of blood volume analysis (BVA) in optimizing individualized therapy for heart failure patients with impaired renal function. Data were presented on 259 patients from three centers at the Technology and Heart Failure Therapeutics Conference (THT), which brought together the world’s leading experts in heart failure innovations at the Westin Boston Seaport in Boston, Massachusetts March 4-6, 2024.
The lead investigator from Duke, Veraprapas Kittipibul M.D., commented during his award-winning presentation that surrogate markers such as “right atrial pressure and capillary wedge pressure had minimal utility to measure blood volume.” The study definitively showed the limitations of these commonly used measures of pressure to guide volume decisions, compared with Daxor’s
The study, titled, ‘Blood Volume Profiles and Correlations with Pressures in Heart Failure with Impaired Renal Function,’ aimed to answer if the degree of renal impairment in heart failure patients impacts volume status, the pressure-volume relationship, and the prevalence and types of anemia.
Veraprapas Kittipibul M.D., lead investigator of the study concluded that:
- Heterogeneity in volume exists across renal function which can only be accurately measured with BVA.
- Patients with large volume expansion had worsening renal function, showing the urgent need for care.
- Pressure-volume correlation is consistently weak across renal function, showing that BVA is the right tool.
- Anemia, especially dilutional anemia, is more prevalent in worse renal function, also detectable by BVA.
“The cornerstone of heart failure care is volume management, and an accurate diagnosis of this is crucial, especially in patients at significant risk for kidney disease,” said Michael Feldschuh, CEO and President of Daxor. “Our BVA technology provides clinicians with
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
